Loading…
Global genomics services company running DNA sequencing for research customers, with major US and UK labs.
Global genomics services company running DNA sequencing for research customers, with major US and UK labs.
Charges per sample for sequencing and analysis, running the samples on instruments bought from sequencer makers, so revenue follows research funding and sample volumes, and the price per sample has fallen over time as the technology improved. Labs outside China, including in the US and UK, serve overseas customers.
In one line: A global genomics-sequencing service, akin to a research-focused Illumina customer/partner.
Moat: narrow (scale, installed base). Large global sequencing capacity and turnaround-time reputation built over a decade.
Headquarters: Beijing, China · Founded: 2011 · Employees: 2,225
Size Novogene (688315.SS) is a China Health Care company (Medical/Nursing Services) with a market value of $1.16B, the 2036th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥18.58 on 6 Nov 2026.
Performance Over six months the shares gained 30.6%, against +10.1% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 5.8% over the last twelve months (peer median +7.9%); the operating margin is 6.6% (peer median 6.7%).
Valuation It trades at 35.7× forward earnings against a peer median of 21.3× (5th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.7 points above its cost of capital (9.5% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.30B | CN¥2.21B | CN¥2.11B | CN¥2.00B | CN¥1.92B |
| Revenue growth | — | +5% | +5% | +4% | — |
| Gross profit | CN¥1.08B | CN¥914M | CN¥901M | CN¥830M | CN¥820M |
| EBITDA | n/a | CN¥292M | CN¥359M | CN¥328M | CN¥336M |
| Net income | CN¥150M | CN¥167M | CN¥197M | CN¥178M | CN¥177M |
| Free cash flow | CN¥238M | CN¥145M | CN¥242M | CN¥241M | CN¥97.1M |
| Capital expenditure | CN¥144M | CN¥104M | CN¥183M | CN¥117M | CN¥217M |
| Total debt | CN¥65.0M | CN¥71.6M | CN¥42.8M | CN¥42.2M | CN¥49.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Novogene 688315.SS | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% |
| BGI Genomics 300676.SZ | $2.39B | -4% | 0% | -14% | 142.2× | n/a |
| Illumina ILMN | $32.2B | +50% | +6% | 21% | 35.7× | 27.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688315.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.9% | +4.0% | 7th lowest of 21 |
| 6-month return | +30.6% | +10.1% | 4th highest of 21 |
| Distance from 52-week high | -20.7% | -18.6% | 9th lowest of 21 |
| Revenue growth (TTM) | +5.8% | +7.9% | 9th lowest of 21 |
| Operating margin | 6.6% | 6.7% | 11th highest of 21 |
| Forward P/E | 35.7× | 21.3× | 5th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 17.1% | 10.1% | 6th most demanding of 18 |
| Growth delivered (Del g) | +8.2% | +10.9% | 8th lowest of 18 |
| Hurdle (Req g minus delivered) | +8.9 pp | +0.2 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | +8.7 pp | -2.4 pp | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 11.1× | -4.6% | +5.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 35.2× | 27.9% | +10.9% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |